Serum levels of soluble carbonic anhydrase IX are decreased in patients with diffuse cutaneous systemic sclerosis compared to those with limited cutaneous systemic sclerosis

BioScience Trends

Volumn 8, Issue 3, 2014, Pages 144-148

  Makino, Katsunari ^a   Jinnin, Masatoshi ^a   Makino, Takamitsu ^a   Kajihara, Ikko ^a   Fukushima, Satoshi ^a   Inoue, Yuji ^a   Ihn, Hironobu ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Carbonic anhydrase IX; Collagen disease; Hypoxia; Systemic sclerosis

Indexed keywords

BIOLOGICAL MARKER; CA9 PROTEIN, HUMAN; CARBONATE DEHYDRATASE; TUMOR ANTIGEN;

ADOLESCENT; ADULT; AGED; BLOOD; CHILD; COLLAGEN DISEASE; DIFFUSE SCLERODERMA; ENZYMOLOGY; FEMALE; HUMAN; MALE; MIDDLE AGED; SYSTEMIC SCLEROSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BIOLOGICAL MARKERS; CARBONIC ANHYDRASES; CHILD; COLLAGEN DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; SCLERODERMA, DIFFUSE; SCLERODERMA, SYSTEMIC; YOUNG ADULT;

EID: 84904859233     PISSN: 18817815     EISSN: 18817823     Source Type: Journal    
DOI: 10.5582/bst.2014.01020     Document Type: Article

References (21)

1. Korn J. Immunologic aspects of scleroderma. Curr Opin Rheumatol. 1989; 1:479-484.
2. Mauch C, Kreig T. Fibroblast-matrix interactions and their role in the pathogenesis of fibrosis. Rheum Dis Clin North Am. 1990; 16:93-107.
3. Müller-Ladner U, Distler O, Ibba-Manneschi L, Neumann E, Gay S. Mechanisms of vascular damage in systemic sclerosis. Autoimmunity. 2009; 42:587-595.
4. Wang G, Jiang B, Rue E, Semenza G. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A. 1995; 92:5510-5514.
5. Lee J, Bae S, Jeong J, Kim S, Kim K. Hypoxia-inducible factor (HIF-1)α: Its protein stability and biological functions. Exp Mol Med. 2004; 36:1-12.
6. Gleadle J, Ratcliffe P. Induction of hypoxia-inducible factor-1, erythropoietin, vascular endothelial growth factor, and glucose transporter-1 by hypoxia: evidence against a regulatory role for Src kinase. Blood. 1997; 89:503-509.
7. Silverstein J, Steen V, Medsger TJ, Falanga V. Cutaneous hypoxia in patients with systemic sclerosis (scleroderma). Arch Dermatol. 1988; 124:1379-1382.
8. Distler O, Distler J, Scheid A, Acker T, Hirth A, Rethage J, Michel B, Gay R, Müller-Ladner U, Matucci-Cerinic M, Plate K, Gassmann M, Gay S. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res. 2004; 95:109-116.
9. Beyer C, Schett G, Gay S, Distler O, Distler J. Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis. Arthritis Res Ther. 2009; 11:220.
10. Swietach P, Patiar S, Supuran C, Harris A, Vaughan-Jones R. The role of carbonic anhydrase 9 in regulating extracellular and intracellular ph in three-dimensional tumor cell growths. J Biol Chem. 2009; 284:20299-20310.
11. Sly W, Hu P. Human carbonic anhydrases and carbonic anhydrase deficiencies. Annu Rev Biochem. 1995; 64:375-401.
12. Zatovicova M, Sedlakova O, Svastova E, Ohradanova A, Ciampor F, Arribas J, Pastorek J, Pastorekova S. Ectodomain shedding of the hypoxia-induced carbonic anhydrase IX is a metalloprotease-dependent process regulated by TACE/ADAM17. Br J Cancer. 2005; 93:1267-1276.
13. Ivanov S, Liao S, Ivanova A, Danilkovitch-Miagkova A, Tarasova N, Weirich G, Merrill M, Proescholdt M, Oldfield E, Lee J, Zavada J, Waheed A, Sly W, Lerman M, Stanbridge E. Expression of hypoxia-inducible cellsurface transmembrane carbonic anhydrases in human cancer. Am J Pathol. 2001; 158:905-919.
14. Wykoff C, Beasley N, Watson P, Turner K, Pastorek J, Sibtain A, Wilson G, Turley H, Talks K, Maxwell P, Pugh C, Ratcliffe P, Harris A. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 2000; 60:7075-7083.
15. Závada J, Závadová Z, Zat'ovicová M, Hyrsl L, Kawaciuk I. Soluble form of carbonic anhydrase IX (CA IX) in the serum and urine of renal carcinoma patients. Br J Cancer. 2003; 89:1067-1071.
16. LeRoy E, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TJ, Rowell N, Wollheim F. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol. 1988; 15:202-205.
17. Ihn H, Sato S, Fujimoto M, Kikuchi K, Igarashi A, Soma Y, Tamaki K, Takehara K. Measurement of anticardiolipin antibodies by ELISA using β2-glycoprotein I (β2-GPI) in systemic sclerosis. Clin Exp Immunol 1996; 105:475-479.
18. Maricq H, Weinrich M, Keil J, Smith E, Harper F, Nussbaum A, LeRoy E, McGregor A, Diat F, Rosal E. Prevalence of scleroderma spectrum disorders in the general population of South Carolina. Arthritis Rheum. 1989; 32:998-1006.
19. Maricq H, McGregor A, Diat F, Smith E, Maxwell D, LeRoy E, Weinrich M. Major clinical diagnoses found among patients with Raynaud phenomenon from the general population. J Rheumatol. 1990; 17:1171-1176.
20. Ihn H, Sato S, Tamaki T, Soma Y, Tsuchida T, Ishibashi Y, Takehara K. Clinical evaluation of scleroderma spectrum disorders using a points system. Arch Dermatol Res. 1992; 284:391-395.
21. Yildirim H, Köçkar F. TGF-β upregulates tumorassociated carbonic anhydrase IX gene expression in Hep3B cells. Cell Biol Int. 2009; 33:1002-1007.